RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;

    Inclusion criterion 1

    Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy.

    Exclusion criterion 13

    Patients who plan to receive radiation within 30 days after transplantation

    Exclusion criterion 15

    Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug);

    Exclusion criterion 19

  3. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    Inclusion criterion 5

  4. White blood cell count(WBC)<2.5×109/L;

    Exclusion criterion 7

    Absolute neutrophil count(ANC)<1.5×109/L;

    Exclusion criterion 8

    Platelets count(PLT)<80×109/L;

    Exclusion criterion 9

    Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min

    Exclusion criterion 10

    AST/ALT/Total bilirubin > 2.5 X ULN;

    Exclusion criterion 11

  5. Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose.

    Inclusion criterion 7

    Patients who are pregnant or breastfeeding

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05294055, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;
  • Patients who had achieved at least partial response (PR);
  • Patients who were eligible for autologous peripheral blood stem cell transplantation
  • Age≥18 and≤65 years;
  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patients who have an estimated life expectancy of more than three months
  • Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose.
  • Patients must be able and willing to give written informed consent prior to any study-related procedures

Exclusion Criteria:

  • Patients who had previously attempted hematopoietic stem cell mobilization;
  • Patients who had undergone previous bone marrow transplantation;
  • Lymphoma patients with bone marrow involvement or patients with MM who had >10% bone marrow involvement at screening ;
  • Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation;
  • Patients with uncontrolled pulmonary infection;
  • Patients who had any of the following laboratory indicators:
  • White blood cell count(WBC)<2.5×109/L;
  • Absolute neutrophil count(ANC)<1.5×109/L;
  • Platelets count(PLT)<80×109/L;
  • Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min
  • AST/ALT/Total bilirubin > 2.5 X ULN;
  • Patients who have received any of the following treatments:
  • Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy.
  • Patients who previously been treated with fludarabine or melphalan;
  • Patients who plan to receive radiation within 30 days after transplantation
  • Patients who had received radiation therapy in the pelvis
  • Patients allergic to Mecapegfilgrastim, pegylated granulocyte stimulating factor, granulocyte stimulating factor, or other formulations expressed by E. coli.
  • Patients who are pregnant or breastfeeding
  • Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug);
  • Patients with other conditions unsuitable for this study according to the investigator's judgment.

Quoted from ClinicalTrials.gov, NCT05294055, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05294055, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05294055